Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update evaluating the safety and immunogenicity of Ad26.RSV.preF and RSV preF Protein vaccine combinations, with expanded safety eval…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Ad26.RSV.preF (Ad26.RSV.preF)
• RSV preF Protein

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Healthy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-09-13